TrialCancer biology & medicine2024

Enhancement of anti-PD-L1 antibody plus anlotinib efficacy due to downregulation of PD-L1 in the micro-conduit endothelium within the tumor: a randomized double-blind trial.

Cuicui Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.